122 related articles for article (PubMed ID: 15966774)
1. Safety of pulmonary administration of gemcitabine in rats.
Gagnadoux F; Le Pape A; Urban T; Montharu J; Vecellio L; Dubus JC; Leblond V; Diot P; Grimbert D; Racineux JL; Lemarié E
J Aerosol Med; 2005; 18(2):198-206. PubMed ID: 15966774
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals.
Min R; Li T; Du J; Zhang Y; Guo J; Lu WL
Can J Physiol Pharmacol; 2008 May; 86(5):288-98. PubMed ID: 18432290
[TBL] [Abstract][Full Text] [Related]
4. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
5. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
6. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
[TBL] [Abstract][Full Text] [Related]
7. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
8. Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.
Pagès PB; Derangere V; Bouchot O; Magnin G; Charon-Barra C; Lokiec F; Ghiringhelli F; Bernard A
Eur J Cardiothorac Surg; 2015 Aug; 48(2):228-35. PubMed ID: 25414426
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Martin C; Lund B; Anderson H; Thatcher N
Anticancer Drugs; 1996 May; 7(3):351-7. PubMed ID: 8792011
[TBL] [Abstract][Full Text] [Related]
11. [Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer].
Sumii T; Fujimori N; Nakamura T; Senju T; Horikawa Y; Funakoshi A
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1261-5. PubMed ID: 16969022
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Witjes JA; Vriesema JL; van der Heijden AG; Peters GJ; Schalken JA
Eur Urol; 2003 Nov; 44(5):615-9. PubMed ID: 14572765
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
Fields MT; Eisbruch A; Normolle D; Orfali A; Davis MA; Pu AT; Lawrence TS
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):785-91. PubMed ID: 10837965
[TBL] [Abstract][Full Text] [Related]
16. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Kouroussis C; Mavroudis D; Kakolyris S; Voloudaki A; Kalbakis K; Souglakos J; Agelaki S; Malas K; Bozionelou V; Georgoulias V
Lung Cancer; 2004 Jun; 44(3):363-8. PubMed ID: 15140550
[TBL] [Abstract][Full Text] [Related]
17. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
